Bruker Receives Notification from Nasdaq Related to Delayed Annual Report on Form 10-K
March 05 2020 - 5:15PM
Business Wire
Bruker Corporation (Nasdaq: BRKR) today announced that it
received a letter from the Listing Qualifications Department of The
Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of
Bruker’s delay in filing its Annual Report on Form 10-K for the
fiscal year ended December 31, 2019 (the “Form 10-K”), Bruker is
not in compliance with the timely filing requirement for continued
listing under Nasdaq Listing Rule 5250(c)(1). The notification
letter has no immediate effect on the listing or trading of
Bruker’s common stock on the Nasdaq Global Select Market.
Bruker filed a Notification of Late Filing on Form 12b-25 on
March 3, 2020, indicating that the filing of the Form 10-K would be
delayed pending completion of an internal investigation into an
allegation recently received in connection with Bruker’s year-end
close, primarily relating to income tax matters including the
effective income tax rate for 2019 and the related income tax
balance sheet accounts.
Nasdaq has informed Bruker that it must submit a plan of
compliance (the “Plan”) within 60 calendar days of receipt of the
letter, or no later than May 4, 2020, addressing how it intends to
regain compliance with Nasdaq’s listing rules and, if Nasdaq
accepts the Plan, it may grant an extension of up to 180 calendar
days from the Form 10-K original filing due date, or until August
31, 2020, to regain compliance.
Bruker is working diligently and intends to file the Form 10-K
as promptly as reasonably practicable after the conclusion of the
investigation and within the 60-day period described above, which
would eliminate the need for Bruker to submit a formal plan to
regain compliance.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
Forward Looking Statements
Any statements contained in this press release which do not
describe historical facts may constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding the expected timing for the
filing of the Form 10-K, the Company’s ability to regain compliance
with the Nasdaq requirements for continued listing and related
matters. Any forward-looking statements contained herein are based
on current expectations, but are subject to risks and uncertainties
that could cause actual results to differ materially from those
indicated, including, but not limited to, risks and uncertainties
relating to the outcome of the previously announced internal
investigation, the failure of the Company to file the Form 10-K on
its expected timeline and, and other risk factors discussed from
time to time in our filings with the Securities and Exchange
Commission, or SEC. These and other factors are identified and
described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year
ended December 31, 2018. We expressly disclaim any intent or
obligation to update these forward-looking statements other than as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200305005878/en/
Miroslava Minkova Director, Investor Relations & Corporate
Development Bruker Corporation T: +1 (978) 663–3660, ext. 1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024